Alteration of correlation between serum pepsinogen concentrations and gastric acid secretion after H. pylori eradication

Journal of Gastroenterology

Volumn 44, Issue 8, 2009, Pages 819-825

  Iijima, Katsunori ^a   Koike, Tomoyuki ^a   Abe, Yasuhiko ^a   Ara, Nobuyuki ^a   Uno, Kaname ^a   Imatani, Akira ^a   Ohara, Shuichi ^a   Shimosegawa, Tooru ^a  

^a TOHOKU UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

Eradication; Gastric acid secretion; H. pylori; Serum pepsinogen

Indexed keywords

BETA LACTAMASE AMPC; CLARITHROMYCIN; METRONIDAZOLE; OMEPRAZOLE; PEPSINOGEN I; PEPSINOGEN II;

ADULT; ARTICLE; CORRELATION ANALYSIS; ENZYME BLOOD LEVEL; ERADICATION THERAPY; GASTRITIS; HELICOBACTER INFECTION; HELICOBACTER PYLORI; HUMAN; MAJOR CLINICAL STUDY; PEPTIC ULCER; PRIORITY JOURNAL; STOMACH ACID SECRETION;

ADULT; BIOLOGICAL MARKERS; CHRONIC DISEASE; FEMALE; FOLLOW-UP STUDIES; GASTRIC ACID; GASTRITIS; HELICOBACTER INFECTIONS; HELICOBACTER PYLORI; HUMANS; LINEAR MODELS; MALE; MIDDLE AGED; PEPSINOGEN A; PEPSINOGEN C; PEPTIC ULCER; RETROSPECTIVE STUDIES;

EID: 69349083129     PISSN: 09441174     EISSN: 14355922     Source Type: Journal    
DOI: 10.1007/s00535-009-0066-2     Document Type: Article

References (49)

1. Hisamichi S. Screening for gastric cancer. World J Surg. 1989;13:31-7.
2. Fukao A, Tsubono Y, Tsuji I, Hisamichi S, Sugahara N, Takano A. The evaluation of screening for gastric cancer in Miyagi Prefecture, Japan: a population-based case-control study. Int J Cancer. 1995;60:45-8.
3. Miki K, Morita M, Sasajima M, Hoshina R, Kanda E, Urita Y. Usefulness of gastric cancer screening using the serum pepsinogen test method. Am J Gastroenterol. 2003;98:735-9.
4. Kitahara F, Kobayashi K, Sato T, Kojima Y, Araki T, Fujino MA. Accuracy of screening for gastric cancer using serum pepsinogen concentrations. Gut. 1999;44:693-7.
5. Samloff IM. Cellular localization of group I pepsinogen in human gastric mucosa by immunofluorescence. Gastroenterology. 1971;61:185-8.
6. Samloff IM, Liebman WM. Cellular localization of the group II pepsinogens in human stomach and duodenum by immunofluorescence. Gastroenterology. 1973;65:36-42.
7. Samloff IM, Varis K, Ihamaki T, Siurala M, Rotter JI. Relationship among serum pepsinogen I, serum pepsinogen II, and gastric mucosal histology. A study in relatives with pernicious anemia. Gastroenterology. 1982;83:204-9.
8. Borch K, Axelsson CK, Halgreen H, Nielson MD, Ledin T, Szesci PB. The ratio of pepsinogen A to pepsinogen C: A sensitive test for atrophic gastritis. Scand J Gastroenterol. 1989;24:870-6.
9. Nakanome C, Akai H, Goto Y. Serum group I pepsinogen levels in patients with peptic ulcer and normal subjects. Tohoku J Exp Med. 1983;139:151-8.
10. Feldman M, Richardson CT, Lam SK, Samloff IM. Comparison of gastric acid secretion rates and serum pepsinogen I and II concentrations in occidental and oriental duodenal ulcer patients. Gastroenterology. 1998;95:630-5.
11. Samloff IM, Secrist DM, Passaro E. A study of relationship between serum group I pepsinogen levels and gastric acid secretion. Gastroenterology. 1975;69:1196-200.
12. Miki K, Ichinose M, Shimizu A, Huang SC, Oka H, Furihata C, et al. Serum pepsinogen as a screening test of extensive chronic gastritis. Gastroenterol Jpn. 1987;22:133-41.
13. Haruma K, Yoshihara M, Sumii K, Tari A, Watanabe C, Kodoi A, et al. Gastric acid secretion, serum pepsinogen I, and serum gastrin in Japanese with gastric hyperplastic polyps or polypoid-type early gastric carcinoma. Scand J Gastroenterol. 1993;28:633-7.
14. Kinoshita Y, Kawanami C, Kishi K, Nakata H, Seino Y, Chiba T. Helicobacter pylori independent chronological change in gastric acid secretion in the Japanese. Gut. 1997;41:452-8.
15. Correa P, Haenszel W, Cuello C, Zavala D, Fontham E, Zarama G, et al. Gastric precancerous process in a high risk population: Cohort follow-up. Cancer Res. 1990;50:4737-40.
16. Siurala M, Varis K, Wiliasalo M. Studies of patients with atrophic gastritis: 10-15-year follow-up. Scand J Gastroenterol. 1966;1:40-8.
17. Svendsen JH, Svendsen CD, Christiansen PM. Gastric cancer risk in achlorhydric patients. A long-term follow-up study. Scand J Gastroenterol. 1986;21:16-20.
18. Yamaji Y, Mitsushima T, Ikuma H, Okamoto M, Yashida H, Kawabe T, et al. Inverse background of Helicobacter pylori antibody and pepsinogen in reflux oesophagitis compared with gastric cancer: Analysis of 5732 Japanese subjects. Gut. 2001;49:335-40.
19. Ohata H, Kitauchi S, Yoshimura N, Mugitani K, Iwane M, Nakamura H, et al. Progression of chronic atrophic gastritis associated with Helicobacter pylori infection increases risk of gastric cancer. Int J Cancer. 2003;109:138-43.
20. Iijima K, Sekine H, Koike T, Imatani A, Ohara S, Shimosegawa T. Serum pepsinogen concentrations as a measure of gastric acid secretion in Helicobacter pylori -negative and -positive Japanese subjects. J Gastroenterol. 2005;40:938-44.
21. Abe Y, Ohara S, Koike T, Sekine H, Iijima K, Kawamura M, et al. The prevalence of Helicobacter pylori infection and the status of gastric acid secretion in patients with Barrett's esophagus in Japan. Am J Gastroenterol. 2004;99:1213-21.
22. Koike T, Ohara S, Sekine H, Iijima K, Abe Y, Kato K, et al. Helicobacter pylori infection prevents erosive reflux oesophagitis by decreasing gastric acid secretion. Gut. 2001;49:330-4.
23. El-Omar EM, Penman I, Ardill JES, Chittajallu RS, Howie C, McColl KEL. Helicobacter pylori infection and abnormalities of acid secretion in patients with duodenal ulcer disease. Gastroenterology. 1995;109:681-91.
24. El-Omar EM, Oien K, El-Nujumi A, Gillen D, Wirz A, Dahill S, et al. Helicobacter pylori infection and chronic gastric acid hyposecretion. Gastroenterology. 1997;113:15-24.
25. Iijima K, Ohara S, Sekine H, Koike T, Kato K, Asaki S, et al. Changes in gastric acid secretion assayed by endoscopic gastrin test before and after Helicobacter pylori eradication. Gut. 2000;46:20-6.
26. Iijima K, Sekine H, Koike T, Imatani A, Ohara S, Shimosegawa T. Long-term effect of Helicobacter pylori eradication on the reversibility of acid secretion in profound hypochlorhydria. Aliment Pharmacol Ther. 2004;19:1181-8.
27. Chittajallu RS, Dorrian CA, Ardill JE, McColl KE. Effect of Helicobacter pylori on serum pepsinogen I and plasma gastrin in duodenal ulcer patients. Scand J Gastroenterol. 1992;27:20-4.
28. Furuta T, Kaneko E, Baba S, Arai H, Futami H. Percentage changes in serum pepsinogens are useful as indices of eradication of Helicobacter pylori. Am J Gastroenterol. 1997;92:84-8.
29. Gisbert JP, Boixeda D, Vila T, de Rafael L, Redondo C, Cantón R, et al. Verification of decreased basal and stimulated serum pepsinogen-I levels is a useful non-invasive method for determining the success of eradication therapy for Helicobacter pylori. Scand J Gastroenterol. 1996;31:103-10.
30. Koike T, Ohara S, Sekine H, Iijima K, Kato K, Toyota T, et al. Increased gastric acid secretion after H. pylori eradication may be a factor for developing reflux oesophagitis. Aliment Pharmacol Ther. 2001;15:813-20.
31. Iijima K, Ohara S, Sekine H, Koike T, Kubata Y, Kato K, et al. A new endoscopic method of gastric acid secretory testing. Am J Gastroenterol. 1998;93:2113-8.
32. Ichinose M, Miki K, Furihara C, Kageyama T, Hayashi R, Niwa H, et al. Radioimmunoassay of serum group I and group II pepsinogen in normal controls and patients with various disorders. Clin Chim Acta. 1982;126:183-91.
33. Yasunaga Y, Shinomura Y, Kanayama S, Miyazaki Y, Bonilla Palacios JJ, Matsuzawa Y. Serum pepsinogen I levels and acid secretion in Helicobacter pylori associated enlarged fold gastritis. Ital J Gastroenterol. 1995;28:457-61.
34. Wagner S, Haruma K, Gladziwa U, Soudah B, Gebel M, Bleck J, et al. Helicobacter pylori infection and serum pepsinogen A, pepsinogen C, and gastrin in gastritis and peptic ulcer: Significance of inflammation and effect of bacterial eradication. Am J Gastroenterol. 1994;89:1211-8.
35. Mossi S, Meyer-Wyss B, Renner EL, Merki H, Gamboni G, Beglinger C. Influence of Helicobacter pylori, sex, and age on serum gastrin and papsinogen concentrations in subjects without symptoms and patients with duodenal ulcers. Gut. 1993;34:752-6.
36. Take S, Mizuno M, Ishiki K, Nagahara Y, Yoshida T, Yokota K, et al. The effect of eradicating helicobacter pylori on the development of gastric cancer in patients with peptic ulcer disease. Am J Gastroenterol. 2005;100:1037-42.
37. Fukase K, Kato M, Kikuchi S, Inoue K, Uemura N, Okamoto S, et al. Effect of eradication of Helicobacter pylori on incidence of metachronous gastric carcinoma after endoscopic resection of early gastric cancer: An open-label, randomised controlled trial. Lancet. 2008;372:392-7.
38. Kamada T, Hata J, Sugiu K, Kusunoki H, Ito M, Tanaka S, et al. Clinical features of gastric cancer discovered after successful eradication of Helicobacter pylori: Results from a 9-year prospective follow-up study in Japan. Aliment Pharmacol Ther. 2005;21:1121-6.
39. Mera R, Fontham ET, Bravo LE, Bravo JC, Piazuelo MB, Camargo MC, et al. Long term follow up of patients treated for Helicobacter pylori infection. Gut. 2005;54:1536-40.
40. Hojo M, Miwa H, Ohkusa T, Ohkura R, Kurosawa A, Sato N. Alteration of histological gastritis after cure of Helicobacter pylori infection. Aliment Pharmacol Ther. 2002;16:1923-32.
41. Shiotani A, Uedo N, Iishi H, Yoshiyuki Y, Ishii M, Manabe N, et al. Predictive factors for metachronous gastric cancer in high-risk patients after successful Helicobacter pylori eradication. Digestion. 2008;78:113-9.
42. Take S, Mizuno M, Ishiki K, Nagahara Y, Yoshida T, Yokota K. et al. Baseline gastric mucosal atrophy is a risk factor associated with the development of gastric cancer after Helicobacter pylori eradication therapy in patients with peptic ulcer diseases. J Gastroenterol. 2007;42(Suppl 17):21-7.
43. Labenz J, Blum AL, Bayerdörffer E, Meining A, Stolte M, Börsch G. Curing Helicobacter pylori infection in patients with duodenal ulcer may provoke reflux esophagitis. Gastroenterology. 1997;112:1442-7.
44. Vaira D, Vakil N, Rugge M, Gatta L, Ricci C, Menegatti M, et al. Effect of Helicobacter pylori eradication on development of dyspeptic and reflux disease in healthy asymptomatic subjects. Gut. 2003;52:1543-7.
45. Wu JC, Chan FK, Ching JY, Leung WK, Hui Y, Leong R, et al. Effect of Helicobacter pylori eradication on treatment of gastro-oesophageal reflux disease: A double blind, placebo controlled, randomised trial. Gut. 2004;53:174-9.
46. Cremonini F, Di Caro S, Delgado-Aros S, Sepulveda A, Gasbarrini G, Gasbarrini A, et al. Meta-analysis: The relationship between Helicobacter pylori infection and gastro-oesophageal reflux disease. Aliment Pharmacol Ther. 2003;18:279-89.
47. Take S, Mizuno M, Ishiki K, Nagahara Y, Yoshida T, Yokota K, et al. Helicobacter pylori eradication may induce de novo, but transient and mild, reflux esophagitis: Prospective endoscopic evaluation. J Gastroenterol Hepatol. 2009;24:107-13.
48. Abe Y, Iijima K, Koike T, Asanuma K, Imatani A, Ohara S, et al. Barrett's esophagus is characterized by the absence of Helicobacter pylori infection and high levels of serum pepsinogen I concentration in Japan. J Gastroenterol Hepatol. 2009;24:129-34.
49. Monkemuller K, Neumann H, Nocon M, Vieth M, Labenz J, Willich SN, et al. Serum gastrin and pepsinogens do not correlate with the different grades of severity of gastro-oesophageal reflux disease: A matched case-control study. Aliment Pharmacol Ther. 2008;28:491-6.